David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.
|Videos|March 28, 2011
Dr. Petrylak Explains Prostate Cancer Clinical Trial Difficulties
Author(s)Daniel P. Petrylak, MD
Daniel P. Petrylak, MD, from Columbia University Medical Center Explains the Difficulties Facing During Prostate Cancer Clinical Trials
Advertisement
Daniel P. Petrylak, MD, Professor of Medicine, Program Director of the Genitourinary Oncology Section in the Division of Hematology/Oncology and Co-Leader, Prostate Cancer in the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center Explains the Difficulties Facing During Prostate Cancer Clinical Trials
Advertisement
Related to this article
Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.
Advertisement
Advertisement
Trending on OncLive
1
NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer
2
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
3
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
4
Updated NCCN Guidelines Recommend Rusfertide Across Polycythemia Vera
5